Nice. Good call on doing it after the huge run when they could have just as easily have done so at $20. I think the market will shrug it off, and might even respond positively.
Since we're the same person, just wanted to suggest that you take a look at CBMX. Excellent shortterm and longterm potential. If they turn profitable this year--good chance they will--look out. Even before that, expect a run similar to ROSG. (Don't feel confident saying that it'll run like TKMR, but it should be a nice run nonetheless.)
Uh huh. The difference between you and me is that I have the common sense to recognize that yes there is a high probability that a few posters have multiple ids, but the wisdom to realize that trying to figure out who does and who doesn't is pointless and futile.
You really, really shouldn't ever become a detective. You'd make a horrible one. But by all means, report me to the SEC. I'm sure they'll take you seriously and it'll have me totally shaking in my boots since according to you, I have multiple ids.
I'm honestly shocked that anyone could be as clueless and paranoid as you are.
Yes, copp. I get it. You think we're the same person. I'm QBert2600 on twitter. By all means, have a look and let me know if you still think we're the same person after doing so.
Your accusations are getting old, and frankly indicative of your lack of intelligence and intuition.
Well, if true, it's a shame that the FDA is putting boys lives on the line while all of this shuffling for power is taking place. As far as I'm concerned, they should just come out and say both companies should file.
How much of that is because of the FDA though? They are very clearly stalling, and it seems intentional and purposeful, which frankly is bull, even if they have every reason to dislike the CEO. They are hurting the parents far more than they're hurting the company. Wouldn't you agree?
You can be certain that the actions in Germany for a drug completely unrelated to DMD will do nothing whatsoever to move the FDA. It's not even on their radar.
Um, no. Not related at all. Quit trying to pump that absolute turd of a stock. SRPT actually has a viable product, unlike NWBO.
Wouldn't you know it, he just about another 4000 shares ($80,000) on March 6. Anybody who doesn't recognize this is purposefully done to keep the share price afloat is naive. (We all know he can afford to buy all of these shares in one large chunk, so why doesn't he?) That being said, Martin seems to understand how the system works, so I imagine he's got a large bag of tricks still up his sleeve. But eventually, it'll all come down to trial results.
"Their is talk on this board that the political rallies and petitions could hurt Eteplirsen's chances of being approved by the FDA. But I believe the opposite."
By whom? I haven't seen anybody do this. Do you have names of regular board posters doing so?
Just kidding. No, I didn't. That guy's an idiot. We'll be at $40 by the summer.
If you "like to chart his calls" then I think you might have too much time on your hands.
Well, his last message yesterday said that that you probably only have one or two days to buy shares before a big move up, so technically, he still isn't wrong. He also never suggested that his price target would hit immediately after the move up. I'd say waiting until the end of March is fair before claiming he is ultimately wrong or right.
Check out ARWR, REGN, GILD, CELG, NLNK, and more importantly, the IBB which is down 2%. Not much if it's an individual stock, but when you're talking about the entire sector, that's pretty significant.
Not all biotechs follow the direction of the IBB, but most do. If they didn't, the IBB wouldn't be red.